Global Primary Immunodeficiency Diseases Market - 2024-2031

Report Overview

The Primary Immunodeficiency Diseases Market reached US$ 7.3 billion in 2023 and is expected to reach US$ 13.0 billion by 2031, growing at a CAGR of 7.6% during the forecast period 2024-2031.

Primary immunodeficiency diseases (PIDDs) are rare, genetic disorders that impair the immune system. Without a functional immune response, people with PIDDs may be subject to chronic, debilitating infections which can increase the risk of developing various types of diseases. Most of the primary immunodeficiency diseases are inherited that is, the disease is passed down from one or two of the parents. There are more than 300 types of primary immunodeficiency disorders, and researchers continue to identify more.

Primary immunodeficiency diseases are caused by genetic variants and can affect anyone, regardless of age, gender, or ethnicity. Some primary immunodeficiency diseases cause symptoms in infancy or early childhood, but others may not present until mid- or even older adulthood. The primary immunodeficiency disorders are sometimes difficult to detect. The diagnosis of primary immunodeficiency disorders requires the expertise of a physician with specialized knowledge and experience.

Market Dynamics: Drivers

Increasing prevalence of primary immunodeficiency diseases

The demand for the primary immunodeficiency diseases market is driven by multiple factors. The rising prevalence of primary immunodeficiency diseases and advancements in the fields of immunology and diagnostics propels the market growth.

According to ncbi.nih.gov, in the entire global population, 1 in every 10,000 human beings are being affected by primary immunodeficiency diseases. In the entire global population, it is estimated that around 6 million people are affected by primary immunodeficiency disorders, out of which 70% of the cases remain undiagnosed. People living with PPID undiagnosed, are more prone to infections, severe autoinflammation, autoimmunity, allergy, and malignancy than normal people.

For primary immunodeficiency diseases, there was a 19% overall increase in patients receiving IgG. Out of all patients diagnosed with a PI defect, 24.3% are on immunoglobulin replacement therapy. It is noteworthy that there was a 27% increase in the number of patients receiving IVIG in the hospital or clinic. According to an article published in nih.gov, as per the survey conducted, there has been an increase of 86.1% in primary immunodeficiency diseases in recent times. The field of primary immunodeficiency is expanding rapidly due to recent advances in sequencing, gene editing tools, and the introduction of new biological drugs and small molecules that target specific checkpoints relevant to immunity and inflammation.

Restraints

Factors such as high cost associated with the treatment, lack of awareness among people, and shortage of skilled professionals are expected to hamper the market.

Market Segment Analysis

The primary immune deficiency disorders market is segmented based on disease type, treatment, end-user, and region.

The immunoglobulin replacement therapy accounted for approximately 56.6% of the primary immunodeficiency diseases market share

The immunoglobulin replacement therapy is expected to hold the largest market share over the forecast period. In this segment, the technological advancements in recent times would drive this market.

Immunoglobulin replacement therapy is a treatment for patients with antibody deficiency that is people who lack antibodies which are known as immunoglobulins. Since antibodies have a vital role in the immune system neutralizing bacteria and viruses and initiating the destruction of microbes by other immune system cells, antibody deficiencies are characterized by an increased risk of infections. Ig replacement therapy treats antibody deficiencies by providing individuals with functional antibodies that allow their bodies to fight off infections.

The immunoglobulin utilized in Ig therapy is made from donated human plasma, the liquid component of blood that contains antibodies. Ig replacement therapy can be given either intravenously (IVIG) or subcutaneously (SCIG). Ig replacement therapy reduces susceptibility to infections, can optimize health, and improves the quality of life for those with antibody deficiencies. As with any treatment, however, individual risks and benefits should be discussed with a healthcare provider.

Market Geographical Analysis

North America accounted for approximately 43.3% of the primary immunodeficiency diseases market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of primary immunodeficiency diseases, and technological advancements in the field of immunology and diagnostics, in this region, help to propel the market.

According to a recent survey conducted by the International Union of Immunological Society, selective IgA deficiency is most prevalent in the US with a percentage of 16.4%. Around 63.4% of the total people having antibody deficiency are from North America. In the US, 55.7% of the patients who are suffering from primary immunodeficiency diseases are male and 44.3% of patients are female.

The presence of major players in this region of North America is one of the reasons for the largest market share. The hematopoietic stem cell transplantation technology is gaining momentum day by day. Hematopoietic stem cell transplantation sometimes referred to as bone marrow transplantation involves administering healthy hematopoietic stem cells to patients with dysfunctional or depleted bone marrow. Targeted therapies are one of the ways to treat the primary immunodeficiency diseases. Targeted therapies include biological agents and small molecule drugs that target specific genes or proteins or components of the immune system. These therapies could be modified antibodies, often referred to as monoclonal antibodies, or chemicals such as cytokines.

Market Segmentation

By Disease Type

• Antibody deficiency
• Agammaglobulinaemia
• IgG Subclass deficiency
• Selective IgA Deficiency
• Others
• Cellular immunodeficiency
• Hyder IgM Syndromes
• Ataxia Telangiectasia
• Wiskott Aldrich syndrome
• Others
• Innate Immune Disorders
• TLR 3 Deficiencies
• Natural killer cell deficiency
• NF Kappa B Essential Modulator Deficiency
• Others

By Treatment

• Immunoglobulin (Ig) Replacement Therapy
• Haemopoietic Stem Cell Transplantation
• Gene Therapy
• Others

By End-User

• Hospitals
• Specialty Clinics
• Academic and Research Centers
• Others

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe
• South America
• Brazil
• Argentina
• Rest of South America
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the primary immunodeficiency diseases market include Abbott Laboratories, AstraZeneca, Pfizer, Baxter International, Inc., Bayer, Bristol Myers Squibb, Eli Lilly, Biotest AG, Grifols, CSL Behring among others.

Key Developments

• Pfizer is always a leading company when it comes to the manufacture of drugs related to immunology. In 2022, Pfizer FDA approval for Panzgya which is a drug that is used for immunotherapy.
• On September 12, 2023, Abbott acquired a company known as Bigfoot Biomedical. Through acquisition, Abbott can prosper in the fields of diabetes care and insulin management systems.
• On August 9, 2022, CSL Behring acquired a company called Vifor Pharmaceuticals. Through this acquisition, CSL Behring has prospered well in the field of therapeutics.

Why Purchase the Report?

• To visualize the primary immunodeficiency diseases segmentation based on disease type, treatment, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of primary immunodeficiency diseases market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The primary immunodeficiency diseases market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies